BIOSGN — Biosergen AB Income Statement
0.000.00%
Last trade - 00:00- SEK97.69m
- SEK74.97m
Annual income statement for Biosergen AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | SAS | SAS | SAS | SAS | SAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | |||||
| Gross Profit | 0 | -0.178 | -0.28 | — | — |
| Selling / General / Administrative Expenses | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 6.23 | 34.1 | 34.1 | 27.3 | 19.2 |
| Operating Profit | -6.23 | -34.1 | -34.1 | -27.3 | -19.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -6.72 | -34.3 | -34 | -27 | -19.2 |
| Net Income After Taxes | -6.72 | -34.3 | -34 | -27 | -19.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.72 | -34.3 | -34 | -27 | -19.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.72 | -34.3 | -34 | -27 | -19.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -12.6 | -64.2 | -47.4 | -31.3 | -11.7 |
| Dividends per Share |